close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sigilon Therapeutics, Inc. - Common Stock (NQ:SGTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sigilon Therapeutics, Inc. - Common Stock

Why These 3 Large Caps Are Bucking the August Slump
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023. 
Via MarketBeat
Topics Economy Stocks
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Equity Investment Life Holding Company (NYSE – AEL), Amedisys, Inc. (Nasdaq – AMED), Sigilon Therapeutics, Inc (Nasdaq – SGTX)
From Brodsky & Smith LLC
Via GlobeNewswire
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX
From Kahn Swick & Foti, LLC
Via Business Wire
Sigilon Therapeutics Inc. (NASDAQ: SGTX) Near the Top of Equities by Percentage Gain on 6/29
Via Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Equity Investment Life Holding Company (NYSE – AEL), Amedisys, Inc. (Nasdaq – AMED), Sigilon Therapeutics, Inc (Nasdaq – SGTX)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Sigilon Therapeutics, Inc (Nasdaq – SGTX)
From Brodsky & Smith LLC
Via GlobeNewswire
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX
From Kahn Swick & Foti, LLC
Via Business Wire
SGTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sigilon Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Sigilon Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today